PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1927716
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1927716
The hematocrit testing Market size was valued at US$1,220.10 Million in 2024, expanding at a CAGR of 5.20% from 2025 to 2032.
The global hematocrit testing market is witnessing steady growth due to the increasing prevalence of blood-related disorders, rising incidence of chronic diseases, and growing demand for routine blood diagnostics. Hematocrit testing plays a vital role in evaluating red blood cell concentration and is widely used in the diagnosis and monitoring of conditions such as anemia, dehydration, and cardiovascular disorders. Technological advancements in point-of-care testing devices and automated hematology analyzers, along with expanding access to diagnostic services, are supporting market growth across both developed and emerging regions.
Hematocrit Testing Market- Market Dynamics
Rising prevalence of anaemia and chronic diseases
The increasing global burden of anaemia, cardiovascular disorders, kidney diseases, and other chronic conditions is a major driver fueling demand for hematocrit testing, as these conditions require regular blood monitoring for effective disease management and treatment assessment. For instance, in April 2024, Mindray introduced the BC-700 series haematology analysers, which offer integrated complete blood count (CBC) and erythrocyte sedimentation rate (ESR) testing within a single platform and are specifically designed for small- to mid-sized laboratories, enhancing testing efficiency and workflow optimisation. Growing awareness among healthcare professionals regarding the importance of early diagnosis, supported by routine health check-ups and screening programs, is further accelerating test adoption. In parallel, continuous advancements in compact diagnostic devices and laboratory automation are improving accessibility, accuracy, and turnaround times, thereby strengthening overall market growth.
The Global Hematocrit Testing Market is segmented on the basis of Product Type, Test Type, End User, and Region.
Based on Product Type, the market is categorised into Hematology Analyzers, Point-of-Care Testing Devices, Centrifuges, and Consumables. Haematology analysers account for a significant share due to their widespread use in hospitals and diagnostic laboratories. Their ability to deliver rapid, accurate, and high-throughput results makes them essential for routine and emergency testing. Continuous technological advancements and integration with laboratory information systems further support their strong adoption.
Based on Test Type, the market is categorised into Automated Hematocrit Tests and Manual Hematocrit Tests. Automated testing dominates the segment owing to higher accuracy, faster turnaround time, and reduced human error. These systems also enable standardised results and improved workflow efficiency in high-volume laboratories. The growing demand for automation in clinical diagnostics further drives this segment.
Based on End User, the market is categorised into Hospitals, Diagnostic Laboratories, Blood Banks, and Others. Hospitals and diagnostic laboratories hold a major share due to high patient volumes and routine blood testing requirements. The increasing prevalence of anaemia and other blood-related disorders further boosts testing demand in these settings.
Hematocrit Testing Market- Geographical Insights
North America leads the hematocrit testing market, attributed to its sophisticated healthcare infrastructure, high diagnostic testing volumes, and a trend towards early adoption of automated laboratory technologies. This region benefits from advanced research and development initiatives, ensuring a continual influx of innovative solutions. Europe follows closely, buoyed by robust public healthcare systems and various widespread screening programs that facilitate routine blood testing. The Asia-Pacific region is anticipated to experience the fastest growth, driven by increasing healthcare expenditures, heightened awareness of anaemia, and the establishment of expanding diagnostic facilities, particularly in China and India. Meanwhile, Latin America and the Middle East & Africa are witnessing steady growth, propelled by improvements in healthcare access and the gradual modernisation of diagnostic laboratories. These advancements are fostering a more integrated patient care approach, enhancing the overall landscape of hematocrit testing across diverse global markets, ensuring better diagnosis and management of related health conditions.
Hematocrit Testing Market- Country Insights
The United States holds a dominant position in the hematocrit testing market, primarily due to its high utilisation of blood tests, robust reimbursement policies, and the presence of leading diagnostic equipment manufacturers. These factors contribute to a well-integrated healthcare system that prioritises timely diagnosis and patient management. In Europe, countries such as Germany, the UK, and France significantly influence the market, thanks to their well-established laboratory networks and proactive preventive healthcare initiatives, which promote regular blood testing among the population. Moreover, China and India are rapidly emerging as high-growth markets, fueled by large patient populations and increasing awareness about diagnostic services. The expansion of hospital and laboratory infrastructure in these countries is facilitating greater access to hematocrit testing. As a result, these regions are witnessing a surge in demand for diagnostic solutions that support effective anaemia management and overall health monitoring, reshaping the global landscape of hematocrit testing.
The hematocrit testing market is moderately competitive, featuring key players such as Abbott Laboratories, Danaher Corporation, Siemens Healthineers, Sysmex Corporation, Roche Diagnostics, Beckman Coulter, Horiba Ltd., Bio-Rad Laboratories, Mindray Medical International, and Nihon Kohden Corporation. These companies are focusing on product innovation, automation, and the expansion of point-of-care testing solutions. Significant investments are being made in advanced haematology analysers, portable testing devices, and integrated diagnostic platforms to enhance accuracy and workflow efficiency. Furthermore, strategic partnerships and geographic expansion are essential strategies to meet the growing demand for routine blood diagnostics within global healthcare systems, for instance, in April and June 2024, HORIBA launched the HELO 2.0 automated platform for high-throughput CBC testing. The series was expanded to include models that integrate CBC/DIFF with ESR results. These advancements streamline laboratory workflows by combining multiple haematology tests. This competitive landscape reflects a commitment to improving patient outcomes through technological advancements and increased accessibility in diagnostics.
In March 2025, the CytoChip CitoCBC analyser received FDA 510(k) clearance and a CLIA waiver. This palm-sized device performs a full CBC, including hematocrit levels. It is designed to provide comprehensive results using a small sample volume.
In November 2025 The ACON Mission Plus Hb Haemoglobin Testing System received renewed FDA 510(k) clearance. This point-of-care platform is designed specifically for accurate haemoglobin measurement. The system also features an integrated calculation for estimated hematocrit levels.